Camurus - Articles and news items

Braeburn and Camurus’ Phase III opioid use disorder trial a success

Industry news / 5 May 2017 / Niamh Marriott, Junior Editor

Braeburn Pharmaceuticals and Camurus announced positive results from Phase 3 trial supporting the safety and efficacy of CAM2038 in opioid use disorder…

Braeburn Pharmaceuticals and Camurus present positive data from opioid use disorder clinical studies

Industry news / 27 October 2016 / Niamh Louise Marriott, Digital Content Producer

Phase 3 study was designed to demonstrate the safety and efficacy of CAM2038 as compared to the sublingual buprenorphine in treating opioid use disorder…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+